Literature DB >> 28543844

Death and liver transplantation within 2 years of onset of drug-induced liver injury.

Paul H Hayashi1, Don C Rockey2, Robert J Fontana3, Hans L Tillmann4, Neil Kaplowitz5, Huiman X Barnhart6, Jiezhan Gu6, Naga P Chalasani7, K Rajender Reddy8, Averell H Sherker9, Jay H Hoofnagle9.   

Abstract

Drug-induced liver injury (DILI) is an important cause of death and indication for liver transplantation (fatality). The role of DILI in these fatalities is poorly characterized, particularly when fatalities occur >26 weeks after DILI onset. We analyzed patients in the US Drug-Induced Liver Injury Network prospective study having a fatal outcome within 2 years of onset. Each case was reviewed by eight network investigators and categorized as DILI having a primary, a contributory, or no role in the fatality. We subcategorized primary role cases as acute, chronic, acute-on-chronic, or acute cholestatic liver failure. For contributory and no role cases, we assigned a primary cause of death. Among 1,089 patients, 107 (9.8%) fatalities occurred within 2 years. DILI had a primary role in 68 (64%), a contributory role in 15 (14%), and no role in 22 (21%); 2 had insufficient data. Among primary role cases, 74% had acute, 13% chronic, 7% acute on chronic, and 6% acute cholestatic failure. For the 15 contributory role cases, common causes of death included sepsis, malignancy, and severe cutaneous reactions with multiorgan failure. For the 22 no role cases, malignancies accounted for most fatalities. Higher bilirubin, coagulopathy, leukocytosis, and thrombocytopenia were independently associated with DILI fatalities. New R ratio Hy's law had a higher positive predictive value for overall fatality (14% versus 10%) and a stronger independent association with DILI fatalities within 26 weeks compared to the original version of Hy's law (hazard ratio, 6.2, 95% confidence interval 3.4-11.1, versus 2.2, 95% confidence interval 1.3-3.7).
CONCLUSIONS: DILI leads directly or indirectly to fatality in 7.6% of cases; 40% of these had nonacute liver failure courses. New R ratio Hy's law better identifies risk for death compared to the original Hy's law. (Hepatology 2017;66:1275-1285).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28543844      PMCID: PMC5605419          DOI: 10.1002/hep.29283

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Authors:  Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar
Journal:  Gastroenterology       Date:  2014-03-27       Impact factor: 22.682

2.  Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.

Authors:  Thierry Gustot; Javier Fernandez; Elisabet Garcia; Filippo Morando; Paolo Caraceni; Carlo Alessandria; Wim Laleman; Jonel Trebicka; Laure Elkrief; Corinna Hopf; Pablo Solís-Munoz; Faouzi Saliba; Stefan Zeuzem; Augustin Albillos; Daniel Benten; José Luis Montero-Alvarez; Maria Teresa Chivas; Mar Concepción; Juan Córdoba; Aiden McCormick; Rudolf Stauber; Wolfgang Vogel; Andrea de Gottardi; Tania M Welzel; Marco Domenicali; Alessandro Risso; Julia Wendon; Carme Deulofeu; Paolo Angeli; François Durand; Marco Pavesi; Alexander Gerbes; Rajiv Jalan; Richard Moreau; Pere Ginés; Mauro Bernardi; Vicente Arroyo
Journal:  Hepatology       Date:  2015-05-29       Impact factor: 17.425

3.  Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method.

Authors:  Don C Rockey; Leonard B Seeff; James Rochon; James Freston; Naga Chalasani; Maurizio Bonacini; Robert J Fontana; Paul H Hayashi
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

4.  Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury.

Authors:  Inmaculada Medina-Caliz; Mercedes Robles-Diaz; Beatriz Garcia-Muñoz; Camilla Stephens; Aida Ortega-Alonso; Miren Garcia-Cortes; Andres González-Jimenez; Judith A Sanabria-Cabrera; Inmaculada Moreno; M Carmen Fernandez; Manuel Romero-Gomez; Jose M Navarro; Ana M Barriocanal; Eva Montane; Hacibe Hallal; Sonia Blanco; German Soriano; Eva M Roman; Elena Gómez-Dominguez; Agustin Castiella; Eva M Zapata; Miguel Jimenez-Perez; Jose M Moreno; Ana Aldea-Perona; Manuel Hernández-Guerra; Martin Prieto; Miguel E Zoubek; Neil Kaplowitz; M Isabel Lucena; Raul J Andrade
Journal:  J Hepatol       Date:  2016-05-13       Impact factor: 25.083

5.  Severe hepatotoxicity following ingestion of Herbalife nutritional supplements contaminated with Bacillus subtilis.

Authors:  Felix Stickel; Sara Droz; Eleonora Patsenker; Katja Bögli-Stuber; Beat Aebi; Stephen L Leib
Journal:  J Hepatol       Date:  2008-10-18       Impact factor: 25.083

6.  Thrombocytopenia Is Associated With Multi-organ System Failure in Patients With Acute Liver Failure.

Authors:  R Todd Stravitz; Caitlyn Ellerbe; Valerie Durkalski; Adrian Reuben; Ton Lisman; William M Lee
Journal:  Clin Gastroenterol Hepatol       Date:  2015-12-10       Impact factor: 11.382

7.  Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.

Authors:  Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins
Journal:  Am J Gastroenterol       Date:  2015-09-08       Impact factor: 10.864

8.  Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

Authors:  Mercedes Robles-Diaz; M Isabel Lucena; Neil Kaplowitz; Camilla Stephens; Inmaculada Medina-Cáliz; Andres González-Jimenez; Eugenia Ulzurrun; Ana F Gonzalez; M Carmen Fernandez; Manuel Romero-Gómez; Miguel Jimenez-Perez; Miguel Bruguera; Martín Prieto; Fernando Bessone; Nelia Hernandez; Marco Arrese; Raúl J Andrade
Journal:  Gastroenterology       Date:  2014-04-01       Impact factor: 22.682

9.  Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.

Authors:  Rajiv Jalan; Faouzi Saliba; Marco Pavesi; Alex Amoros; Richard Moreau; Pere Ginès; Eric Levesque; Francois Durand; Paolo Angeli; Paolo Caraceni; Corinna Hopf; Carlo Alessandria; Ezequiel Rodriguez; Pablo Solis-Muñoz; Wim Laleman; Jonel Trebicka; Stefan Zeuzem; Thierry Gustot; Rajeshwar Mookerjee; Laure Elkrief; German Soriano; Joan Cordoba; Filippo Morando; Alexander Gerbes; Banwari Agarwal; Didier Samuel; Mauro Bernardi; Vicente Arroyo
Journal:  J Hepatol       Date:  2014-06-17       Impact factor: 25.083

10.  Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011.

Authors:  William M Lee; R Todd Stravitz; Anne M Larson
Journal:  Hepatology       Date:  2012-03       Impact factor: 17.425

View more
  15 in total

1.  Predicting fatalities in serious idiosyncratic drug-induced liver injury-a matter of choosing the best Hy's law.

Authors:  Fernando Bessone
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-18

2.  Mortality associated with drug-induced liver injury (DILI).

Authors:  Einar S Björnsson; Helgi K Björnsson
Journal:  Transl Gastroenterol Hepatol       Date:  2017-12-19

3.  Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort.

Authors:  Rachel J Church; Gerd A Kullak-Ublick; Jiri Aubrecht; Herbert L Bonkovsky; Naga Chalasani; Robert J Fontana; Jens C Goepfert; Frances Hackman; Nicholas M P King; Simon Kirby; Patrick Kirby; John Marcinak; Sif Ormarsdottir; Shelli J Schomaker; Ina Schuppe-Koistinen; Francis Wolenski; Nadir Arber; Michael Merz; John-Michael Sauer; Raul J Andrade; Florian van Bömmel; Thierry Poynard; Paul B Watkins
Journal:  Hepatology       Date:  2018-06-27       Impact factor: 17.425

4.  Development and Validation of a Model Consisting of Comorbidity Burden to Calculate Risk of Death Within 6 Months for Patients With Suspected Drug-Induced Liver Injury.

Authors:  Marwan Ghabril; Jiezhun Gu; Lindsay Yoder; Laura Corbito; Amit Ringel; Christian D Beyer; Raj Vuppalanchi; Huiman Barnhart; Paul H Hayashi; Naga Chalasani
Journal:  Gastroenterology       Date:  2019-07-11       Impact factor: 22.682

Review 5.  Tools for causality assessment in drug-induced liver disease.

Authors:  Hans L Tillmann; Ayako Suzuki; Huiman X Barnhart; Jose Serrano; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2019-05       Impact factor: 3.287

Review 6.  Drug-Induced Liver Injury: Highlights of the Recent Literature.

Authors:  Mark Real; Michele S Barnhill; Cory Higley; Jessica Rosenberg; James H Lewis
Journal:  Drug Saf       Date:  2019-03       Impact factor: 5.606

7.  A galactose-mediated targeting nanoprobe for intracellular hydroxyl radical imaging to predict drug-induced liver injury.

Authors:  Bailing Ma; Mi Lu; Bo-Yang Yu; Jiangwei Tian
Journal:  RSC Adv       Date:  2018-06-15       Impact factor: 4.036

Review 8.  The diagnostic role of miR-122 in drug-induced liver injury: A systematic review and meta-analysis.

Authors:  Yiqi Liu; Ping Li; Liang Liu; Yilian Zhang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

9.  Long-Term Outcomes After Drug-Induced Liver Injury.

Authors:  Paul H Hayashi; Einar S Bjornsson
Journal:  Curr Hepatol Rep       Date:  2018-07-02

10.  Cytokine profiles in acute liver injury-Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group.

Authors:  Herbert L Bonkovsky; Huiman X Barnhart; David M Foureau; Nury Steuerwald; William M Lee; Jiezhun Gu; Robert J Fontana; Paul J Hayashi; Naga Chalasani; Victor M Navarro; Joseph Odin; Andrew Stolz; Paul B Watkins; Jose Serrano
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.